Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

NCT03170895 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

AML
FLT3-ITD Mutation

Interventions

DRUG: Sorafenib
DRUG: Omacetaxine Mepesuccinate Injection

Sponsor

The University of Hong Kong